Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
Article
Burrell, Matthew O, Stany, Michael, Rutledge, James et al. (2013). Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
. JOURNAL OF CLINICAL ONCOLOGY, 31(15_suppl), e16525-e16525. 10.1200/jco.2013.31.15_suppl.e16525
Burrell, Matthew O, Stany, Michael, Rutledge, James et al. (2013). Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
. JOURNAL OF CLINICAL ONCOLOGY, 31(15_suppl), e16525-e16525. 10.1200/jco.2013.31.15_suppl.e16525